KaloBios Pharmaceuticals Inc. said Wednesday it had received a delisting letter from the Nasdaq Stock Market , days after former Chief Executive Martin Shkreli was charged with securities fraud.

The biotech also said its independent accounting firm, Marcum LLP, and its interim chief financial officer, Christopher Thorn, had resigned.

KaloBios said it hadn’t yet determined if it would appeal the Nasdaq delisting and has until Monday to do so. If KaloBios doesn’t appeal, its stock would be suspended from trading on Nasdaq at the opening of business on Dec. 30.

It wasn’t immediately clear if KaloBios’s stock would resume trading before the delisting. The stock has been halted at $23.59 since the charges against Mr. Shkreli became public last week.

Shares of KaloBios have been on quite a ride. The stock hit an intraday low of 44 cents on Nov. 16 after announcing plans to wind down operations but surged to $45.82 a week later on news that Mr. Shkreli had led an investor group to acquire a majority stake in the company.